Scope of report
- The report provides a snapshot of the global therapeutic landscape of Alpha 1-antitrypsin deficiency.
- The report assesses Alpha 1-antitrypsin deficiency pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Alpha 1-antitrypsin deficiency pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Alpha 1-antitrypsin deficiency ranging from discovery to pre-registration and undisclosed stages.
Alnylam Pharmaceuticals, Alpha Therapeutic Corporation, Apollo Therapeutics, Applied Genetic Technologies Corporation, Arcturus Therapeutics, AriZeke Pharmaceuticals, Arrowhead Research Corporation, Bayer, CEVEC Pharmaceuticals, CoTherix, CSL Behring, Editas Medicine, GTC Biotherapeutics, LFB Biotechnologies, ID Pharma, Inhibrx, Intellia Therapeutics, Intrexon Corporation, Intronn, Isis Pharmaceuticals, Kamada, Mirus Bio Corporation, PharmaLogika, PlasmaTech Biopharmaceuticals, Polyphor, PPL Therapeutics PLC, Promethera Biosciences, ProMetic Life Sciences, Promosome, Protease Sciences, Sangamo BioSciences, Vertex Pharmaceuticals
Human amniocyte-derived protein therapeutics, Genome editing therapeutics, POL 6014, A1A OC1, Gene therapies, AAT-Fc – InhibRx, Gene editing therapeutics, Biotherapeutic proteins, Stem cell therapies, Genetic disorder therapeutics, Antisense drug therapies, Human plasma-derived biologics
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800